Treace Medical Concepts Inc (TMCI)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $345.50M
Last updated: Nov 17, 2026 at 11:05 AM ET
Treace Medical Concepts Inc (TMCI) Earnings: Report Dates and Results
Treace Medical Concepts (TMCI) is expected to report earnings on Feb 25, 2027. In the quarter ended Sep 30, 2026, Treace Medical Concepts reported EPS of -$0.19, above the -$0.26 estimate. It beat the EPS estimate in each of the last 9 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
TMCI has an expected report date of Feb 25, 2027.
TMCI Earnings Call
The latest TMCI earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 22 quarters below that had an estimate, TMCI beat 16, missed 5 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $48.25M, down 3.9% from $50.21M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.19 | -$0.26 | N/A | +26.92% | Beat | N/A | 1 | 0 up, 1 down | Nov 6, 2026 | $48.25M |
| Jun 30, 2026 | -$0.24 | -$0.30 | -$0.30 - -$0.30 | +20.00% | Beat | N/A | 1 | 0 up, 1 down | Aug 7, 2026 | $45.38M |
| Mar 31, 2026 | -$0.28 | -$0.31 | -$0.31 - -$0.31 | +9.68% | Beat | N/A | 1 | 0 up, 1 down | May 8, 2026 | $47.20M |
| Dec 31, 2025 | -$0.08 | -$0.15 | N/A | +48.52% | Beat | N/A | 1 | 2 up, 0 down | Feb 27, 2026 | $62.52M |
| Sep 30, 2025 | -$0.22 | -$0.27 | -$0.28 - -$0.26 | +18.52% | Beat | N/A | 3 | 0 up, 3 down | Nov 6, 2025 | $50.21M |
| Jun 30, 2025 | -$0.28 | -$0.29 | -$0.31 - -$0.26 | +3.45% | Beat | N/A | 3 | 0 up, 2 down | Aug 7, 2025 | $47.39M |
| Mar 31, 2025 | -$0.25 | -$0.30 | -$0.33 - -$0.28 | +16.67% | Beat | N/A | 3 | 1 up, 0 down | May 8, 2025 | $52.57M |
| Dec 31, 2024 | $0.00 | -$0.04 | -$0.07 - -$0.02 | +96.25% | Beat | N/A | 4 | 0 up, 3 down | Feb 27, 2025 | $68.71M |
| Sep 30, 2024 | -$0.25 | -$0.26 | -$0.30 - -$0.25 | +3.85% | Beat | N/A | 6 | 0 up, 0 down | Nov 5, 2024 | $45.09M |
| Jun 30, 2024 | -$0.28 | -$0.28 | -$0.32 - -$0.26 | 0.00% | In line | N/A | 7 | 0 up, 0 down | Aug 6, 2024 | $44.45M |
| Mar 31, 2024 | -$0.28 | -$0.31 | -$0.37 - -$0.27 | +9.68% | Beat | N/A | 7 | 0 up, 0 down | May 7, 2024 | $51.11M |
| Dec 31, 2023 | -$0.10 | -$0.09 | -$0.15 - -$0.04 | -11.11% | Miss | N/A | 7 | 0 up, 0 down | Feb 27, 2024 | $62.21M |
| Sep 30, 2023 | -$0.28 | -$0.26 | -$0.31 - -$0.24 | -7.69% | Miss | N/A | 7 | 0 up, 1 down | Nov 9, 2023 | $40.76M |
| Jun 30, 2023 | -$0.20 | -$0.23 | -$0.27 - -$0.19 | +13.04% | Beat | N/A | 6 | 0 up, 0 down | Aug 8, 2023 | $41.95M |
| Mar 31, 2023 | -$0.23 | -$0.24 | -$0.29 - -$0.19 | +4.17% | Beat | N/A | 6 | 0 up, 0 down | May 8, 2023 | $42.20M |
| Dec 31, 2022 | -$0.08 | -$0.14 | -$0.17 - -$0.11 | +42.86% | Beat | N/A | 4 | 0 up, 0 down | Mar 7, 2023 | $49.77M |
| Sep 30, 2022 | -$0.22 | -$0.29 | -$0.30 - -$0.28 | +24.14% | Beat | N/A | 4 | 0 up, 0 down | Nov 8, 2022 | $33.05M |
| Jun 30, 2022 | -$0.23 | -$0.19 | -$0.24 - -$0.18 | -21.05% | Miss | N/A | 4 | 0 up, 0 down | Aug 9, 2022 | $29.97M |
| Mar 31, 2022 | -$0.16 | -$0.17 | -$0.25 - -$0.14 | +5.88% | Beat | N/A | 4 | 0 up, 0 down | May 5, 2022 | $29.05M |
| Dec 31, 2021 | -$0.12 | -$0.01 | -$0.01 - $0.00 | N/A | N/A | -300.0% | 4 | N/A | Mar 3, 2022 | $33.44M |
| Sep 30, 2021 | -$0.12 | -$0.11 | -$0.13 - -$0.11 | -9.09% | Miss | N/A | 4 | 0 up, 0 down | Nov 4, 2021 | $21.62M |
| Jun 30, 2021 | -$0.10 | -$0.13 | -$0.15 - -$0.10 | +23.08% | Beat | N/A | 4 | N/A | Aug 5, 2021 | $20.65M |
| Mar 31, 2021 | -$0.07 | -$0.06 | N/A | -16.67% | Miss | N/A | N/A | N/A | Apr 26, 2021 | $18.71M |
| Dec 31, 2020 | $0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 3, 2021 | $24.10M |
| Dec 31, 2019 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.83, after -$0.81 the year before. It was -$0.05 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.83 | N/A |
| Dec 31, 2024 | -$0.81 | N/A |
| Dec 31, 2023 | -$0.81 | N/A |
| Dec 31, 2022 | -$0.69 | N/A |
| Dec 31, 2021 | -$0.41 | -783.3% |
| Dec 31, 2020 | $0.06 | N/A |
| Dec 31, 2019 | -$0.05 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,700 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,722 | 8 | |
| 2026Q2 | Jun 30, 2026 | 5,010 | 9 | |
| 2026Q1 | Mar 31, 2026 | 5,069 | 8 | |
| 2025Q4 | Dec 31, 2025 | 6,683 | 10 | |
| 2025Q3 | Sep 30, 2025 | 3,649 | 6 | |
| 2025Q2 | Jun 30, 2025 | 3,891 | 8 | |
| 2025Q1 | Mar 31, 2025 | 4,154 | 7 | |
| 2024Q4 | Dec 31, 2024 | 5,814 | 10 |
2026Q3 Earnings Call
Opening remarks
Trip Taylor Investor Relations Good morning, everyone, and welcome to our third quarter 2026 earnings conference call. Participating from the company today will be John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer. John and Mark will discuss our third quarter financial results and our 2026 outlook. We will then host a question-and-answer session following our prepared remarks. Our press release can be found in the Investor Relations section of our website at investors.treace.com. This call is being recorded and will be archived in the Investor Relations section of our website. Before we begin, we would like to remind you that it is our intent that all forward-looking statements made during today's call will be protected under the Private Securities Litigation Reform Act of 2000. Any statements that relate to expectations or predictions of future events and market trends, as well as our estimated results or performance, are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. All forward-looking statements are based upon currently available information, and Treace Medical assumes no obligation to update these statements. Accordingly, you should not place undue reliance on these statements. Please refer to our SEC filings, including our 2025 Form 10-K and our Form 10-Q for the third quarter of 2026, filed before the market opened today, November 6, which can be found in the Investor Relations section of our website at investors.treace.com, for a detailed presentation of risks. With that, I will now turn the call over to John. Thank you, Trip.
John T. Treace CEO Good morning, everyone, and thank you for joining us on our third quarter 2026 earnings conference call. We are encouraged by our third quarter performance, driven by double-digit case volume growth and continued market share gains from increasing adoption of our comprehensive portfolio of best-in-class bunion systems and our expanding line of new technologies. During the quarter, we continued to advance our strategic priorities with investments in new products, creating opportunities to build on the foundation that Lapiplasty has established as our surgeon customers adopt more of our new products into their practices. As we expand our presence across a broader range of foot and ankle procedures, we expect the new 2026 product introductions that I will discuss this morning to expand our total addressable market by approximately $700 million. This strategy has allowed us to leverage our commercial resources to pursue high-impact growth opportunities while maintaining disciplined expense management. We believe this approach positions us to enhance our growth trajectory while improving operating performance over time.
Frequently Asked Questions About TMCI
When is Treace Medical Concepts's next earnings date?
Treace Medical Concepts's next earnings report is expected for Feb 25, 2027.
Did TMCI beat earnings estimates last quarter?
Yes. Treace Medical Concepts reported EPS of -$0.19 for the quarter ended Sep 30, 2026, above the -$0.26 estimate, a 26.92% surprise.
What EPS do analysts expect from TMCI next quarter?
The consensus EPS estimate for Treace Medical Concepts for the quarter ending Dec 31, 2026 is -$0.08 from 7 analysts, with estimates from -$0.11 to -$0.05.
How often does TMCI beat earnings estimates?
Treace Medical Concepts beat the EPS estimate in each of the last 9 quarters, with an average surprise of +27.09%.
TMCI pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts